Yungjin Pharm. Co., Ltd.

KSE 003520.KS

Yungjin Pharm. Co., Ltd. Shareholders' Equity for the year ending December 31, 2023: USD 68.84 M

Yungjin Pharm. Co., Ltd. Shareholders' Equity is USD 68.84 M for the year ending December 31, 2023, a -3.04% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Yungjin Pharm. Co., Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 71.00 M, a -19.13% change year over year.
Yungjin Pharm. Co., Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 87.79 M, a -16.43% change year over year.
Yungjin Pharm. Co., Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 105.05 M, a 5.28% change year over year.
Yungjin Pharm. Co., Ltd. Shareholders' Equity for the year ending December 31, 2019 was USD 99.78 M, a 0.00% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

KSE: 003520.KS

Yungjin Pharm. Co., Ltd.

CEO	Mr. Chae-Joon Lee
IPO Date	Jan. 8, 2001
Location	South Korea
Headquarters	13, Olympic-ro 35da-gil
Employees	574
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pet Food Plastics Soft Drinks & Sodas

Description

Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea. It provides cephalosporin antibiotic, antipsychotic, cardiovascular, and nutrition products. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. is a subsidiary of KT&G Corporation.

Key trends

Past 5 years